

<b>NCT ID</b>	NCT03069469
<b>Title</b>	Study of DCC-3014 in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2017-03-03
<b>Location</b>	California, United States Colorado, United States Florida, United States Massachusetts, United States New York, United States Oregon, United States Tennessee, United States Australia Canada France Italy Netherlands Poland Spain United Kingdom
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	DCC-3014
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT03829462
<b>Title</b>	Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients
<b>Phase</b>	Phase 3
<b>Date Added</b>	2019-02-04
<b>Location</b>	France
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Irinotecan, Regorafenib
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT04096417
<b>Title</b>	Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations
<b>Phase</b>	Phase 2
<b>Date Added</b>	2019-09-19
<b>Location</b>	Arizona, United States Georgia, United States Minnesota, United States North Carolina, United States Tennessee, United States Wisconsin, United States
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Pemigatinib
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT04793958
<b>Title</b>	Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

<b>Phase</b>	Phase 3
<b>Date Added</b>	2021-03-11
<b>Location</b>	Alabama, United States
	Arizona, United States
	Arkansas, United States
	California, United States
	Colorado, United States
	Connecticut, United States
	Florida, United States
	Georgia, United States
	Illinois, United States
	Indiana, United States
	Iowa, United States
	Louisiana, United States
	Maryland, United States
	Massachusetts, United States
	Michigan, United States
	Minnesota, United States
	Missouri, United States
	Nebraska, United States
	Nevada, United States
	New Jersey, United States
	New York, United States
	North Carolina, United States
	Ohio, United States
	Oklahoma, United States
	Pennsylvania, United States
	South Carolina, United States
	Tennessee, United States
	Texas, United States
	Utah, United States
	Virginia, United States
	Washington, United States
	West Virginia, United States
	Wisconsin, United States
	Argentina
	Australia
	Austria
	Belgium
	Brazil
	Canada
	China
	Colombia
	Czechia
	Denmark
	Finland
	France
	Germany
	Greece
	Hong Kong
	Ireland
	Italy
	Korea, Republic of
	Malaysia
	Mexico
	Netherlands
	Poland
	Portugal
	Puerto Rico
	Romania
	Singapore
	Spain
	Taiwan
	Thailand
	Ukraine
	United Kingdom

<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	cetuximab, FOLFIRI Regimen, mFOLFOX6 Regimen, MRTX849
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT04599140
<b>Title</b>	SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2020-10-22
<b>Location</b>	Texas, United States
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	CXCR1/2 Inhibitor SX-682, Nivolumab
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT03650348
<b>Title</b>	PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
<b>Phase</b>	Phase 1
<b>Date Added</b>	2018-08-28
<b>Location</b>	California, United States Louisiana, United States New York, United States Ohio, United States Texas, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	PRS-343 in Combination with Atezolizumab, Tecentriq
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT04724239
<b>Title</b>	A Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma
<b>Phase</b>	Phase 2
<b>Date Added</b>	2021-01-26
<b>Location</b>	China
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	chidamide, IBI305, Sintilimab
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT02537418
<b>Title</b>	Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens
<b>Phase</b>	Phase 1
<b>Date Added</b>	2015-09-01
<b>Location</b>	Canada
<b>Prior IO Allowed</b>	Yes

<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	durvalumab, Tremelimumab, Imfinzi
<b>Tags</b>	MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT03626922
<b>Title</b>	Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients
<b>Phase</b>	Phase 1
<b>Date Added</b>	2018-08-13
<b>Location</b>	Florida, United States Illinois, United States Michigan, United States Minnesota, United States Pennsylvania, United States
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Dexamethasone, oxaliplatin, Pembrolizumab, Pemetrexed, Alimta, Eloxatin, Keytruda
<b>Tags</b>	MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT04185883
<b>Title</b>	Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
<b>Phase</b>	Phase 1
<b>Date Added</b>	2019-12-04
<b>Location</b>	Arizona, United States California, United States Colorado, United States Connecticut, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Iowa, United States Maryland, United States Michigan, United States Missouri, United States New York, United States North Carolina, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Australia Austria Belgium Canada Germany Italy Japan Netherlands South Korea Spain Taiwan United Kingdom

Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	afatinib, AMG 404, Atezolizumab, carboplatin, pemetrexed, docetaxel, everolimus, FOLFIRI, FOLFOX, MVASI® (bevacizumab-awwb), palbociclib, panitumumab, Pembrolizumab, RMC-4630, Sotorasib, TNO155, Trametinib
Tags	MSI-H/ MMRd, MSS/ MMRp